A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome

References

• Finnegan LP. Perinatal substance abuse: comments and perspectives. [Review] [40 refs]. Semin Perinatol. 1991; 15(4)331–9
   PubMed Web of Science ®Google Scholar
• Shankaran S, Das A, Bauer CR, Bada HS, Lester B, Wright LL, et al. Association between patterns of maternal substance use and infant birth weight, length, and head circumference. Pediatrics. 2004; 114(2)226–34
   Web of Science ®Google Scholar
• Gillogley KM, Evans AT, Hansen RL, Samuels SJ, Batra KK. The perinatal impact of cocaine, amphetamine, and opiate use detected by universal intrapartum screening. Am J Obstet Gynecol. 1990; 163(5 Pt 1)1535–42
   PubMed Web of Science ®Google Scholar
• Schneiderman JF. Nonmedical drug and chemical use in pregnancy. Maternal-fetal toxicology: a clinician's guideSecond edition, JF Schneiderman. M Dekker, New York 1994; 301–19
   Google Scholar
• Brown HL, Britton KA, Mahaffey D, Brizendine E, Hiett AK, Turnquest MA. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol. 1998; 179(2)459–63
   PubMed Web of Science ®Google Scholar
• Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction. 2000; 95(2)239–44
   PubMed Web of Science ®Google Scholar
• Schindler SD, Eder H, Ortner R, Rohrmeister K, Langer M, Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction. 2003; 98(1)103–10
   PubMed Web of Science ®Google Scholar
• Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003; 70(2 Suppl)S87–S101
   PubMed Web of Science ®Google Scholar
• Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction. 2004; 99(2)209–14
   PubMed Web of Science ®Google Scholar
• Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S, the Groupe d'Etudes Grossesse et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006;82(3):250–7.
   PubMed Web of Science ®Google Scholar
• El-Mohandes A, Herman AA, Nabil El-Khorazaty M, Katta PS, White D, Grylack L. Prenatal care reduces the impact of illicit drug use on perinatal outcomes. J Perinatol. 2003; 23(5)354–60
   PubMedGoogle Scholar
• Finnegan LP. Neonatal abstinence syndrome. Current therapy in neonatal-perinatal medicineFirst edition, N Nelson. BC Decker Inc, Ontario 1984; 314–20
   Google Scholar
• Pihkala J, Hakala T, Voutilainen P, Raivio K. Characteristic of recent fetal growth curves in Finland]. [Review] [18 refs]. Duodecim. 1989; 105(18)1540–6
   PubMedGoogle Scholar
• Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.[see comment]. Lancet. 2003; 361(9358)662–8
   PubMed Web of Science ®Google Scholar
• Kuhlman JJ, Jr, Lalani S, Magluilo J, Jr, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 1996; 20(6)369–78
   PubMed Web of Science ®Google Scholar
• Robinson SE. Effects of perinatal buprenorphine and methadone exposures on striatal cholinergic ontogeny. Neurotoxicol Teratol. 2002; 24(2)137–42
   PubMed Web of Science ®Google Scholar
• Belcheva MM, Bohn LM, Ho MT, Johnson FE, Yanai J, Barron S, et al. Brain opioid receptor adaptation and expression after prenatal exposure to buprenorphine. Brain Res Dev Brain Res. 1998; 111(1)35–42
   PubMedGoogle Scholar
• Hu S, Sheng WS, Lokensgard JR, Peterson PK. Morphine induces apoptosis of human microglia and neurons. Neuropharmacology. 2002; 42(6)829–36
   PubMed Web of Science ®Google Scholar
• Lester BM, Tronick EZ, LaGasse L, Seifer R, Bauer CR, Shankaran S, et al. The maternal lifestyle study: effects of substance exposure during pregnancy on neurodevelopmental outcome in 1-month-old infants. Pediatrics. 2002; 110(6)1182–92
   PubMed Web of Science ®Google Scholar
• Gourarier L, Lorene C, Aubisson S, Peyret E. 1998–1999 substitution treatment and birth among heroin dependent women in France: a prospective study about 249 cases. Drug Alcohol Depend. 2001; 63(Supplement)58
   Google Scholar
• Kayemba-Kays S, Laclyde JP. Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction. 2003; 98(11)1599–604
   PubMed Web of Science ®Google Scholar
• Dashe JS, Sheffield JS, Olscher DA, Todd SJ, Jackson GL, Wendel GD. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol. 2002; 100(6)1244–49
   PubMed Web of Science ®Google Scholar
• Kandall SR, Gaines J, Habel L, Davidson G, Jessop D. Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspring. J Pediatr. 1993; 123(1)120–6
   PubMed Web of Science ®Google Scholar
• Suguihara C, Bancalari E. Substance abuse during pregnancy: effects on respiratory function in the infant. [Review] [70 refs]. Semin Perinatol. 1991; 15(4)302–9
   PubMed Web of Science ®Google Scholar